Jonathan Wolleben
Stock Analyst at Citizens
(4.53)
# 220
Out of 5,182 analysts
245
Total ratings
51.65%
Success rate
24.86%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DBVT DBV Technologies | Maintains: Market Outperform | $45 → $47 | $21.04 | +123.38% | 17 | Mar 27, 2026 | |
| KALV KalVista Pharmaceuticals | Maintains: Market Outperform | $29 → $28 | $19.90 | +40.70% | 7 | Mar 26, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Market Outperform | $152 → $155 | $86.29 | +79.63% | 9 | Mar 20, 2026 | |
| SPRB Spruce Biosciences | Maintains: Market Outperform | $180 → $170 | $70.50 | +141.15% | 10 | Mar 10, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $105 → $96 | $37.23 | +157.86% | 19 | Mar 2, 2026 | |
| GPCR Structure Therapeutics | Maintains: Market Outperform | $120 → $113 | $53.48 | +111.29% | 12 | Feb 27, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $102 → $112 | $103.78 | +7.92% | 14 | Feb 26, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $140 → $132 | $94.17 | +40.17% | 14 | Feb 26, 2026 | |
| SION Sionna Therapeutics | Initiates: Market Outperform | $63 | $40.49 | +55.59% | 1 | Feb 24, 2026 | |
| QNCX Quince Therapeutics | Downgrades: Market Perform | n/a | $0.10 | - | 3 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $527 → $745 | $546.89 | +36.22% | 15 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $35 | $5.32 | +557.89% | 9 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $11 → $10 | $5.56 | +79.86% | 10 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $15 → $14 | $3.34 | +319.16% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $27 → $25 | $9.02 | +177.16% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $20 | $5.87 | +240.72% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $20 → $29 | $8.49 | +241.58% | 18 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $4.79 | +275.78% | 13 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $52 | $28.41 | +83.03% | 12 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $1.71 | +367.84% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $0.70 | +2,049.00% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $6.54 | +190.52% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $32.99 | +15.19% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $40.49 | +23.49% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $39.95 | +125.28% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $124.95 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $488.97 | -0.81% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $64 | $8.42 | +660.55% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $26.11 | -8.08% | 1 | May 12, 2023 |
DBV Technologies
Mar 27, 2026
Maintains: Market Outperform
Price Target: $45 → $47
Current: $21.04
Upside: +123.38%
KalVista Pharmaceuticals
Mar 26, 2026
Maintains: Market Outperform
Price Target: $29 → $28
Current: $19.90
Upside: +40.70%
Rhythm Pharmaceuticals
Mar 20, 2026
Maintains: Market Outperform
Price Target: $152 → $155
Current: $86.29
Upside: +79.63%
Spruce Biosciences
Mar 10, 2026
Maintains: Market Outperform
Price Target: $180 → $170
Current: $70.50
Upside: +141.15%
Crinetics Pharmaceuticals
Mar 2, 2026
Maintains: Market Outperform
Price Target: $105 → $96
Current: $37.23
Upside: +157.86%
Structure Therapeutics
Feb 27, 2026
Maintains: Market Outperform
Price Target: $120 → $113
Current: $53.48
Upside: +111.29%
Protagonist Therapeutics
Feb 26, 2026
Maintains: Market Outperform
Price Target: $102 → $112
Current: $103.78
Upside: +7.92%
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Market Outperform
Price Target: $140 → $132
Current: $94.17
Upside: +40.17%
Sionna Therapeutics
Feb 24, 2026
Initiates: Market Outperform
Price Target: $63
Current: $40.49
Upside: +55.59%
Quince Therapeutics
Jan 30, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $0.10
Upside: -
Jan 20, 2026
Maintains: Market Outperform
Price Target: $527 → $745
Current: $546.89
Upside: +36.22%
Nov 14, 2025
Maintains: Market Outperform
Price Target: $33 → $35
Current: $5.32
Upside: +557.89%
Nov 13, 2025
Maintains: Market Outperform
Price Target: $11 → $10
Current: $5.56
Upside: +79.86%
Nov 7, 2025
Maintains: Market Outperform
Price Target: $15 → $14
Current: $3.34
Upside: +319.16%
Nov 5, 2025
Maintains: Market Outperform
Price Target: $27 → $25
Current: $9.02
Upside: +177.16%
Nov 3, 2025
Initiates: Market Outperform
Price Target: $20
Current: $5.87
Upside: +240.72%
Oct 1, 2025
Maintains: Market Outperform
Price Target: $20 → $29
Current: $8.49
Upside: +241.58%
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $4.79
Upside: +275.78%
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $28.41
Upside: +83.03%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $1.71
Upside: +367.84%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $0.70
Upside: +2,049.00%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $6.54
Upside: +190.52%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $32.99
Upside: +15.19%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $40.49
Upside: +23.49%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $39.95
Upside: +125.28%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $124.95
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $488.97
Upside: -0.81%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $64
Current: $8.42
Upside: +660.55%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $26.11
Upside: -8.08%